Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SRA737 + Anti–PD-L1 Therapy and Low-Dose Gemcitabine Shows Promise for SCLC

Publish date:: May 21, 2019

Key clinical point: SRA737 with anti–PD-L1 therapy and low-dose gemcitabine led to tumor regression in a preclinical small cell lung cancer (SCLC) model.

Major finding: The triple combination led to tumor regression as early as 14 days, with CRs in 8 of 10 cases.

Study details: A preclinical mouse model study.

Disclosures: Dr. Sen reported having no disclosures.

Citation:

Sen T et al. AACR 2019, Abstract LB-148.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Immuno-oncology

Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors,

Dual immunotherapy goes the distance in MSI-H colorectal cancer,

T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study,

CAR T cells produce complete responses in T-cell malignancies,

CAR T-cell therapy advances in CLL,